Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: A retrospective study

European Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2003, Pages 57-64

  Tamminga, Wim J ^a   Wemer, Johan ^c   Oosterhuis, Berend ^a   De Boer, Anthonius ^d   Vranckx, Stan ^e   Drenth, Ben F H ^e   De Zeeuw, Rokus A ^b   De Leij, Lou F M H ^b   Jonkman, Jan H G ^b  

^a PRA International USA   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Applied NanoSystems   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e Psychiatric Hospital Dennenoord   (Netherlands)

Author keywords

Polymorphic drug metabolism; Psychiatric patients; Psychotropic drugs

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; PSYCHOTROPIC AGENT; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ALLELE; ARTICLE; DRUG METABOLISM; DRUG USE; FEMALE; GENE DUPLICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; NETHERLANDS; PARKINSONISM; PHARMACY; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0038130873     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0562-x     Document Type: Article

References (33)

1. Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
2. Daly AK, Cholerton S, Gregory W, Idle JR (1993) Metabolic polymorphisms. Pharmacol Ther 57:129-160
3. Meyer UA, Zanger UM (1997) Molecular mechanism of genetic polymorphism of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296
4. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201
5. Griese E-U, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in German population. Pharmacogenetics 8:15-26
6. Edeki T (1996) Clinical importance of genetic polymorphism of drug oxidation. Mount Sinai J Med 63:290-300
7. Spina E, Caputi AP (1994) Pharmacogenetic aspects in the metabolism of psychotropic drug: pharmacokinetics and clinical implications. Pharmacol Res 29:121-137
8. Meyer UA, Amrein R, Balant LP, Bertilsson L, Eichelbaum M, Guenter TW, Henauer S, Jackson P, Laux G, Mikkelsen H, Peck C, Pollock B, Priest R, Sjöqvist F, Delini-Stula A (1996) Antidepressant and drug-metabolizing enzymes - expert group report. Acta Psychiatr Scand 93:71-79
9. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E (1997) Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51:395-398
10. Cohen LJ, DeVane CL (1996) Clinical implications of antidepressant pharmacokinetics and pharmacogenetics Ann Pharmacother 30:1471-1480
11. Dahl ML, Bertilsson L (1993) Genetically variable metabolism of antidepressants and neuroleptic drug in man. Pharmacogenetics 3:61-70
12. Dahl-Puustinen ML, Lidén A, Alm C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 46:78-81
13. Bertilsson L, Dahl ML (1996) Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5:200-223
14. Vandel P, Haffen E, Vandel S, Bonin B, Nezelhof S, Sechter D, Broly F, Biouard P, Dalery J (1999) Drug extrapyrimidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 55:659-665
15. Chen S, Chou WH, Blouin RA, Mao Z, Humpries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534
16. De Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ (1998) Pilot study of cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 155:1278-1280
17. Chou WH, Yan FX, De Leon J, Barnhill J, Roger T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ (2000) Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 20:246-251
18. Lau HS, de Boer A, Beuning KS, Porsius A (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619-625
19. Stüven T, Griese E-U, Kroemer HK, Eichelbaum M, Zanger UM (1996) Rapid detection of CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction. Pharmacogenetics 6:417-421
20. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM (1996) Ultrarapid metabolizers of debrisoquin: characterisation and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34
21. Steijns LWS, van der Weide J (1998) Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 44:914-917
22. Flockhart DA Web site of the Georgetown University Medical Center (Washington DC, USA) on http://www.dml.georgetown.edu/depts/pharmacology/davetab.html
23. WHO (1997) WHO collaborating Centre for Drug Statistics Methodology. ATC index with DDD's (Oslo, Norway)
24. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Wilffert B, De Leij LFMH, De Zeeuw RA, Jonkman JHG (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55:177-184
25. Arthur H, Dahl ML, Siwers B, Sjöqvist F (1995) Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Pschopharmacol 15:211-216
26. Spiget O, Hedenmalm K, Dahl ML, Wiholm BE, Dahlqvist R (1997) Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 96:379-384
27. Gex-Fabry M, Balant-Gorgia AE, Balant LP (1999) Clomipramine concentrations as a predictor of delayed response: a naturalistic study. Eur J Clin Pharmacol 54:895-902
28. Aitchison JA, Munro J, Wright P, Smith S, Makoff AJ, Sachse C, Sham PC, Murray RM, Collier DA, Kerwin RW (1999) Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol 48:388-394
29. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435-443
30. Sekine Y, Rikihisa T, Ogata H, Echizen H, Arakawa Y (1999) Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 55:583-587
31. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JFW, Sham P, Collier DA, Muray RM, Kerwin RW (2000) Pharmacogenetic prediction of clozapine response. The Lancet 355:1615-1616
32. Dahl M-L, Sjöqvist F (2000) Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 22:114-117
33. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F, Spina E, Bröckmöller J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104:173-192